ArticleJournal of enzyme inhibition and medicinal chemistry2025
Identification of a novel and high affinity MIF inhibitor
Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Macrophage migration inhibitory factor (MIF): a Janus-faced cytokine in viral pathogenesis and host defense.Immunologic research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage migration inhibitory factor (MIF) plays a crucial role in disrupting immune homeostasis and was overexpressed in immune cells. The inhibitors of MIF inhibit the release of inflammatory factors to treat sepsis. Herein, a series of compounds (termed as Hits 1-6) were discovered based on pharmacophore modelling, molecular docking, and interaction analysis. The biaryltriazole inhibitor 3a was used as the positive control. MST and ITC experiments showed that compared to 3a, Hit-1 possessed the highest affinity with MIF. MD simulations exhibited that Hit-1 stably bound to the active pocket of MIF. Pull down experiment showed that Hit-1 could interfere with the binding of MIF to CD74. Furthermore, RT-qPCR demonstrated that Hit-1 suppressed the release of pro-inflammatory cytokines in macrophages including TNF-α, IL-6, and IL-1β. These data demonstrate that Hit-1 may be a promising and high-affinity candidate compound treating sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.